Trials / Completed
CompletedNCT00337883
A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
A Phase II, Multicenter, Open-Label Trial of the Safety and Efficacy of Tarceva (Erlotinib Hydrochloride) in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, open-label, multicenter trial of single-agent treatment with Tarceva in patients with histologically confirmed GBM in first relapse. This study seeks to estimate the objective response rate and will investigate whether response rate is related to EGFR amplification status.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib HCl (OSI-774) |
Timeline
- Start date
- 2003-07-01
- Completion
- 2005-10-01
- First posted
- 2006-06-20
- Last updated
- 2014-03-04
Source: ClinicalTrials.gov record NCT00337883. Inclusion in this directory is not an endorsement.